A newly approved blood test by the FDA could revolutionize Alzheimer’s diagnosis, allowing for detection up to a decade before symptoms manifest, thus offering a critical opportunity for early intervention.
A transformative blood test capable of identifying Alzheimer’s disease in its preclinical stages has received approval from the U.S. Food and Drug Administration (FDA). This advancement could significantly alter public health strategies regarding the neurodegenerative condition, which currently affects more than 7 million Americans, a number projected to nearly double by 2050 according to the Alzheimer’s Association.
The ability to detect Alzheimer’s disease five to ten years before the onset of symptoms such as memory loss or language difficulties enables healthcare providers to initiate treatment during a crucial window when therapies are likely to be most effective. Former Centers for Disease Control and Prevention (CDC) Director Dr. Robert Redfield described this breakthrough as a pivotal moment in modern medicine during an interview with EWTN News Nightly.
“The FDA has approved, actually, a blood test that can give you high suspicion that you have Alzheimer’s,” Dr. Redfield stated, underscoring the potential impact of this diagnostic tool. Traditional methods of diagnosing Alzheimer’s have relied heavily on the presence of clinical dementia, often resulting in late-stage identification of the disease. However, medical experts now recognize three distinct stages of Alzheimer’s, with the initial two stages occurring without any overt clinical symptoms.
Catching the Disease in Its Preclinical Stages
The newly approved blood test enables the detection of subtle brain changes and neuronal damage well before the appearance of cognitive symptoms, allowing patients to explore treatment options at an earlier stage. Dr. Redfield emphasized the importance of early diagnosis, advocating for awareness among patients regarding the benefits of identifying Alzheimer’s before it progresses to clinical disease. “I’ve been a big advocate of trying to get people to realize it’s to their advantage to get diagnosed early before they have clinical disease,” he remarked.
A Call for Universal Screening
In light of this breakthrough, Dr. Redfield is urging federal health authorities to include routine blood screenings for Alzheimer’s as a standard part of adult healthcare. He argues that proactive measures should be taken rather than waiting for symptoms to prompt testing. “I think they should be much more proactive,” he stated, adding that he has recommended to officials, including Secretary Robert F. Kennedy and Dr. Mehmet Oz at the Centers for Medicare & Medicaid Services (CMS), that all Americans over the age of 50 should undergo the blood test to detect preclinical Alzheimer’s.
Dr. Redfield advocates for cognitive screening through blood work to become as commonplace as routine checks for vital organs during annual Medicare wellness visits. “For those of us over 50 that begin to assess our mental function, we do everything to assess whether our heart is working and if our lungs are working, if our kidneys are working: We need to do the same thing in terms of Alzheimer’s,” he advised.
Bridging the Gap Between Innovation and Patient Care
Dr. Redfield’s push for integrating routine blood testing into clinical practice is informed by his return to patient care after his tenure at the CDC. In assessing patients with cognitive dysfunction associated with long COVID, he frequently encountered unexpected diagnoses of underlying Alzheimer’s disease.
“And one of the hallmarks in those patients is they have significant cognitive dysfunction. … Occasionally, I find that the patients not only have long COVID, but, lo and behold, when I worked them up, I find out they also have Alzheimer’s,” he shared. This experience has fueled his frustration regarding the slow adoption of medical advances in patient care.
With the introduction of the blood test, alongside new FDA-approved treatments and research-backed lifestyle adjustments, the prognosis for Alzheimer’s is shifting from a previously untreatable fate to a more manageable condition. “Alzheimer’s is a very difficult disease. It’s a huge economic burden in the United States, not only for the patients, but also for the caregivers,” Dr. Redfield noted. He emphasized the need for a proactive approach in confronting Alzheimer’s, stating, “To be candid, you know, I believe … we just have to deal with what we have to deal with and help patients have the courage to confront the illnesses that they have, and then help them try to address those as effectively as they can.”
